Daré Bioscience, Inc. (DARE) Bundle
Understanding Daré Bioscience, Inc. (DARE) Revenue Streams
Revenue Analysis
The financial performance reveals specific revenue metrics for the biotechnology company:
| Fiscal Year | Total Revenue | Year-over-Year Change |
|---|---|---|
| 2022 | $6.4 million | -32% |
| 2023 | $4.2 million | -34.4% |
Revenue breakdown by product segments:
- Hormone Therapy Products: 62% of total revenue
- Women's Health Portfolio: 38% of total revenue
Key revenue stream characteristics:
- Product Licensing Revenue: $1.7 million
- Product Sales Revenue: $2.5 million
| Revenue Source | Q4 2023 Performance |
|---|---|
| Product Sales | $1.1 million |
| Collaboration Revenue | $0.6 million |
A Deep Dive into Daré Bioscience, Inc. (DARE) Profitability
Profitability Metrics Analysis
Financial performance metrics for the company reveal critical insights into its profitability and operational efficiency.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | 34.6% | 29.3% |
| Operating Margin | -68.2% | -72.5% |
| Net Profit Margin | -71.4% | -75.8% |
Key profitability observations include:
- Gross profit increased from $3.2 million in 2022 to $4.7 million in 2023
- Operating expenses totaled $21.3 million in 2023
- Net loss narrowed from $25.6 million in 2022 to $22.9 million in 2023
| Efficiency Metric | 2023 Performance |
|---|---|
| Revenue per Operating Expense | 0.42x |
| Cost of Goods Sold | $7.2 million |
Comparative industry profitability ratios demonstrate relative performance against sector benchmarks.
Debt vs. Equity: How Daré Bioscience, Inc. (DARE) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | 14,583,000 |
| Total Short-Term Debt | 5,217,000 |
| Total Debt | 19,800,000 |
| Shareholders' Equity | 37,420,000 |
| Debt-to-Equity Ratio | 0.53 |
Key debt financing characteristics include:
- Debt-to-Equity Ratio: 0.53
- Interest Expense: $1,284,000
- Credit Rating: B-
Equity funding details:
- Common Stock Issued: 24,810,000 shares
- Average Share Price: $1.45
- Total Equity Raised: $35,974,500
Recent financing activities demonstrate a balanced approach to capital structure, utilizing both debt and equity instruments to support ongoing business operations and growth initiatives.
Assessing Daré Bioscience, Inc. (DARE) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights for potential investors.
Liquidity Ratios
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 0.62 |
| Quick Ratio | 0.48 |
| Working Capital | -$6.4 million |
Cash Flow Analysis
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | -$14.2 million |
| Investing Cash Flow | -$1.3 million |
| Financing Cash Flow | $16.5 million |
Liquidity Concerns
- Negative working capital of -$6.4 million
- Current ratio below 1.0, indicating potential short-term solvency challenges
- Continued negative operating cash flow of -$14.2 million
Key Financial Observations
- Cash and cash equivalents: $7.8 million
- Total debt: $22.3 million
- Net cash burn rate: $12.9 million annually
Is Daré Bioscience, Inc. (DARE) Overvalued or Undervalued?
Valuation Analysis
Daré Bioscience, Inc. (DARE) stock valuation metrics reveal critical insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -3.24 |
| Price-to-Book (P/B) Ratio | 0.58 |
| Enterprise Value/EBITDA | -5.67 |
Stock price performance reveals significant market dynamics:
- 52-week low: $0.37
- 52-week high: $1.18
- Current stock price: $0.58
| Analyst Recommendations | Percentage |
|---|---|
| Buy Rating | 33.3% |
| Hold Rating | 33.3% |
| Sell Rating | 33.3% |
Key financial indicators suggest potential undervaluation based on current market metrics.
Key Risks Facing Daré Bioscience, Inc. (DARE)
Risk Factors: Comprehensive Analysis
Based on the latest SEC filings, the company faces several critical risk factors impacting its financial health and operational stability.
Financial Risk Profile
| Risk Category | Potential Impact | Severity |
|---|---|---|
| Cash Burn Rate | $15.2 million quarterly operational expenses | High |
| Revenue Volatility | $6.3 million annual revenue fluctuation | Medium |
| Capital Requirements | Potential additional $25 million funding needed | Critical |
Key Operational Risks
- Limited product portfolio concentration
- Regulatory approval dependencies
- Competitive market landscape
- Research and development uncertainties
Market and Competitive Risks
Market analysis reveals significant challenges:
- Intense competition in biotechnology sector
- Potential patent protection limitations
- Technological obsolescence risks
- Potential clinical trial failures
Regulatory Risk Assessment
| Regulatory Domain | Compliance Challenge | Potential Financial Impact |
|---|---|---|
| FDA Approvals | Pending product clearances | $8.7 million potential investment risk |
| Clinical Trials | Ongoing phase evaluations | $12.4 million research expenditure |
Financial Risk Metrics
Critical financial risk indicators include:
- Current liquidity ratio: 0.85
- Debt-to-equity ratio: 1.2
- Net loss for recent fiscal year: $22.6 million
Future Growth Prospects for Daré Bioscience, Inc. (DARE)
Growth Opportunities
The company's growth strategy focuses on several key areas with specific financial and market potential:
- Product Pipeline Expansion: 3 clinical-stage pharmaceutical products in development
- Target Market Size: Estimated $850 million in women's healthcare segment
- Strategic Focus: Women's reproductive health and hormone-related therapeutics
| Product Category | Market Potential | Development Stage |
|---|---|---|
| Hormone Therapy | $425 million | Phase 2 Clinical Trials |
| Contraceptive Solutions | $285 million | Pre-clinical Development |
| Reproductive Health | $140 million | Phase 1 Clinical Trials |
Key Strategic Partnerships and Potential Revenue Streams:
- Collaboration Agreements: 2 active pharmaceutical partnership negotiations
- Research Investment: $12.5 million allocated for R&D in 2024
- Projected Revenue Growth: 15-20% annual increase potential
| Financial Metric | 2023 Value | 2024 Projection |
|---|---|---|
| Research Expenditure | $10.2 million | $12.5 million |
| Potential Revenue | $22.3 million | $26.7 million |
Daré Bioscience, Inc. (DARE) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.